202
Participants
Start Date
April 30, 2015
Primary Completion Date
June 30, 2016
Study Completion Date
June 30, 2016
Secukinumab
Secukinumab 150 mg, 1 ml liquid formulation in a pre-filled pen for s.c. injection
Fumaric acid
Fumaric acid initial therapy (tablet contains 30 mg dimethylfumarate, 67 mg ethylhydrogenfumarate calcium salt, 5 mg ethylhydrogenfumarate magnesium salt, 3 mg ethylhydrogenfumarate zinc salt) and Fumaric acid maintenance therapy (tablet contains 120 mg dimethylfumarate, 87 mg ethylhydrogenfumarate calcium salt, 5 mg ethylhydrogenfumarate magnesium salt, 3 mg ethylhydrogenfumarate zinc salt)
Novartis Investigative Site, Berlin
Novartis Investigative Site, Berlin
Novartis Investigative Site, Berlin
Novartis Investigative Site, Berlin
Novartis Investigative Site, Berlin
Novartis Investigative Site, Schwerin
Novartis Investigative Site, Hamburg
Novartis Investigative Site, Hamburg
Novartis Investigative Site, Stade
Novartis Investigative Site, Hamburg
Novartis Investigative Site, Lübeck
Novartis Investigative Site, Kiel
Novartis Investigative Site, Hanover
Novartis Investigative Site, Bielefeld
Novartis Investigative Site, Bochum
Novartis Investigative Site, Bochum
Novartis Investigative Site, Essen
Novartis Investigative Site, Münster
Novartis Investigative Site, Bad Bentheim
Novartis Investigative Site, Osnabrück
Novartis Investigative Site, Bonn
Novartis Investigative Site, Selters
Novartis Investigative Site, Frankfurt
Novartis Investigative Site, Darmstadt
Novartis Investigative Site, Ludwigshafen
Novartis Investigative Site, Mannheim
Novartis Investigative Site, Heidelberg
Novartis Investigative Site, München
Novartis Investigative Site, Erlangen
Novartis Investigative Site, Gera
Novartis Investigative Site, Halle
Novartis Investigative Site, Quedlinburg
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY